Market news

Avantor has appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective 21 September 2026, placing him in charge of its global finance organization, including planning, accounting, treasury, tax, investor relations and internal audit. Garner’s three decades of finance and public company leadership, including prior CFO roles and extensive investor relations experience, could meaningfully influence Avantor’s capital allocation and communication with the...

Detailed price information for Avantor Inc (AVTR-N) from The Globe and Mail including charting and trades.

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Avantor (AVTR) has named Todd Garner as chief financial officer, effective immediately, the company

AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.

AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.

Avantor (AVTR) has an average rating of hold and mean price target of $14.33, according to analysts

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Detailed price information for Avantor Inc (AVTR-N) from The Globe and Mail including charting and trades.

Detailed price information for Avantor Inc (AVTR-N) from The Globe and Mail including charting and trades.

Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Avantor (AVTR) has an average rating of hold and mean price target of $14.33, according to analysts

Avantor (AVTR) has an average rating of hold and mean price target of $14.33, according to analysts

AVTR tops Q2 earnings and revenue estimates as VWR returned to organic growth early, prompting higher 2026 revenues and earnings guidance.

The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Avantor (NYSE:AVTR) reported second-quarter 2026 results that exceeded its expectations on several measures, supported by a return to organic growth in its VWR Distribution & Services segment, strong free cash flow and progress under its Revival operational improvement program. Revenue totaled

Moby summary of Avantor, Inc.'s Q2 2026 earnings call

Avantor (AVTR) delivered earnings and revenue surprises of +10.53% and +4.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Life sciences company Avantor (NYSE:AVTR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $1.69 billion. Its non-GAAP profit of $0.21 per share was 11% above analysts’ consensus estimates.

Avantor Inc (AVTR) raises 2026 guidance amid strong VWR segment performance and strategic debt reduction.

Life sciences company Avantor (NYSE:AVTR) will be reporting results this Wednesday before market hours. Here’s what investors should know.

Avantor (NYSE:AVTR), through its NuSil brand, has expanded its collaboration with the Population Council. The partnership focuses on supporting the development of a three-month dapivirine vaginal ring for HIV prevention. The product is aimed at improving HIV prevention options for women, particularly in regions with higher prevalence. Avantor, a supplier of materials and solutions to the life sciences and advanced technologies sectors, is deepening its role in global health through this...

Avantor (AVTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVTR vs. ICLR: Which Stock Is the Better Value Option?

Avantor (AVTR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AVTR's shares jump nearly 7% as NuSil expands its HIV prevention partnership for a three-month dapivirine vaginal ring.

Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, announced today the expansion of a collaboration between its NuSil® brand, a premier global manufacturer of high-purity silicones suitable for use in medical devices and drug-device combination products, and the Population Council, an international nonprofit research organization, to support the development of the Council's new three-month dapivirine

Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here. The letter states that the portfolio holdings are attractive now based on both P/V and P/FCF metrics. However, the Fund returned 3.87% in the quarter, significantly lagging the S&P 500’s […]

Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research.

Avantor stock has had a difficult run, with longer term shareholders still well underwater. However, the current market price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach, and the broader valuation checks also lean toward the shares looking cheap rather than expensive. Avantor has declined 71.4% over the past 5 years, which means current holders are anchored to a long period of weak returns despite the recent rebound. Renewed interest from...

Avantor, Inc. previously announced that it would release its second-quarter 2026 financial results before the U.S. market opened on Wednesday, July 29, accompanied by an earnings call and webcast for investors. A separate disclosure highlighted renewed interest from institutional investors, with several hedge funds, including Greenhaven Associates, significantly increasing their Avantor holdings, signaling growing institutional engagement with the company. With institutional investors...